Helmut Forstbauer
Troisdorf, NW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 43 publications
Refining Risk Assessment for Adjuvant CDK4/6 Inhibitors beyond Trial Inclusion Criteria: Integrating Recurrence Score and Endocrine Responsiveness according to ADAPT.
Journal: Breast care (Basel, Switzerland)
Published: January 09, 2026
Vulnerability to Infections and Secondary Immunodeficiencies in Patients with Non-Hodgkin's Lymphomas Starting Anti-CD20 Antibody-Containing Therapies.
Journal: Oncology research and treatment
Published: August 18, 2025
Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N = 7914).
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: July 10, 2025
Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Journal: JAMA network open
Published: February 26, 2025
HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TN.
Journal: Breast cancer research : BCR
Published: September 26, 2024
Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trial.
Journal: Molecular cancer
Published: September 24, 2024
TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: July 20, 2024
Deep learning to predict breast cancer sentinel lymph node status on INSEMA histological images.
Journal: European journal of cancer (Oxford, England : 1990)
Published: September 11, 2023
Intraoperative or postoperative stereotactic radiotherapy for brain metastases: time to systemic treatment onset and other patient-relevant outcomes.
Journal: Journal of neuro-oncology
Published: August 04, 2023
Efficacy and quality of life for FOLFOX/bevacizumab +/- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trial.
Journal: British journal of cancer
Published: July 14, 2023
Outcome assessment of intraoperative radiotherapy for brain metastases: results of a prospective observational study with comparative matched-pair analysis.
Journal: Journal of neuro-oncology
Published: April 06, 2023
Last Updated: 09/26/2026